DeepMed Research

Fruquintinib

Generic Name: Fruquintinib

Brand Names: Fruzaqla

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉N_₃O_₅

CAS Number: 1194506-26-7

Unique Ingredient Identifier: 49DXG3M5ZW

Background: Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication: 本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。

Clinical Trials

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Tucidinostat
Drug: Fruquintinib
Drug: Sintilimab
Drug: Bevacizumab

First Posted Date: 2024-07-12

Last Posted Date: 2024-12-03

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 430

Registration Number: NCT06497985

Locations: 🇨🇳
Rui-Hua Xu, Guangzhou, Guangdong, China

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Phase 1

Not yet recruiting

Conditions: To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma
To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer
Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer

Interventions: Drug: Pirfenidone
Drug: Fruquintinib
Drug: Pembrolizumab

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-03

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 25

Registration Number: NCT06484153

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma
Immune Checkpoint Inhibitors
Anti-angiogenic Therapy
Second-line Treatment

Interventions: Drug: Fruquintinib

First Posted Date: 2024-06-06

Last Posted Date: 2024-12-31

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 36

Registration Number: NCT06446154

Locations: 🇨🇳
Sun Yat-sen university cancer center, Guangzhou, Guangdong, China

Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer

Phase 2

Not yet recruiting

Conditions: Rectal Cancer

Interventions: Drug: CapeOX
Drug: Fruquintinib and Tislelizumab combined with mCapeOX

First Posted Date: 2024-06-05

Last Posted Date: 2024-06-05

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 132

Registration Number: NCT06443671

Locations: 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, Haidian District, China

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Fluorouracil
Drug: Oxaliplatin

First Posted Date: 2024-06-04

Last Posted Date: 2024-06-04

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 84

Registration Number: NCT06441565

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

Phase 2

Recruiting

Conditions: Fruquintinib
Raltitrexed
S-1

Interventions: Drug: Fruquintinib
Drug: S-1
Drug: raltitrexed

First Posted Date: 2024-05-23

Last Posted Date: 2025-01-22

Lead Sponsor: Meng Qiu

Target Recruit Count: 66

Registration Number: NCT06427005

Locations: 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: Fruquintinib
Drug: PD-1inhibitor
Drug: albumin paclitaxel

First Posted Date: 2024-05-16

Last Posted Date: 2025-01-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT06417892

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Early Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Sintilimab
Drug: Inulin

First Posted Date: 2024-04-04

Last Posted Date: 2024-04-04

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 30

Registration Number: NCT06347198

Locations: 🇨🇳
Min Jin, Wuhan, Hubei, China

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Phase 1

Recruiting

Conditions: Metastatic Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Fruquintinib in combination with Sintilimab and CAPEOX

First Posted Date: 2024-03-26

Last Posted Date: 2024-03-26

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 70

Registration Number: NCT06329973

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Not Applicable

Recruiting

Conditions: Renal Cell Carcinoma, Clear Cell, Somatic

Interventions: Drug: Fruquintinib and Everolimus

First Posted Date: 2024-03-19

Last Posted Date: 2024-03-19

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 36

Registration Number: NCT06317298

Locations: 🇨🇳
Peking University First Hospital, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy